In the case of WT1 peptide vaccines, several approaches have confirmed their low risk of side effects and feasibility for the treatment of solid tumors like pancreatic cancer [52] as well as AML and myelodysplastic syndrome (MDS) [43]. The gene discussed is WT1; the disease is acute myeloid leukemia.